Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

• Published in: Clinical cancer research 2005-05, Vol.11 (9), p.3385-3391
• Main Authors: RAMANATHAN, Ramesh K, TRUMP, Donald L, BRUFSKY, Adam M, WONG, Michael K. K, TUTCHKO, Susan, EGORIN, Merrill J, EISEMAN, Julie L, BELANI, Chandra P, AGARWALA, Sanjiv S, ZUHOWSKI, Eleanor G, JING LAN, POTTER, Douglas M, IVY, S. Percy, RAMALINGAM, Sakkaraiappan
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Area Under Curve; Benzoquinones; Biological and medical sciences; clinical trial; Diarrhea - chemically induced; Dose-Response Relationship, Drug; Estradiol - blood; Fatigue - chemically induced; Female; Follicle Stimulating Hormone - blood; geldanamycin; heat shock proteins; HSP70 Heat-Shock Proteins - blood; HSP90 Heat-Shock Proteins - antagonists & inhibitors; HSP90 Heat-Shock Proteins - blood; Humans; Hydrocortisone - blood; Lactams, Macrocyclic; Leukocytes, Mononuclear - drug effects; Leukocytes, Mononuclear - metabolism; Leukopenia - chemically induced; Luteinizing Hormone - blood; Male; Medical sciences; Middle Aged; Nausea - chemically induced; Neoplasms - blood; Neoplasms - drug therapy; Pharmacology. Drug treatments; phase I study; Progesterone - blood; Protein Serine-Threonine Kinases - antagonists & inhibitors; Rifabutin - adverse effects; Rifabutin - analogs & derivatives; Rifabutin - pharmacokinetics; Rifabutin - therapeutic use; Testosterone - blood; Treatment Outcome; Vomiting - chemically induced
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-04-2322

Purpose: 17-(Allylamino)-17-demethoxygeldanamycin (17AAG), a benzoquinone antibiotic, down-regulates oncoproteins by binding specifically to heat shock protein 90 (HSP90). We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics. Experimental Design: Escalating doses of 17AAG were given i.v. over 1 or 2 hours on a weekly × 3 schedule every 4 weeks to cohorts of three to six patients. Plasma pharmacokinetics of 17AAG and 17-(amino)-17-demethoxygeldanamycin (17AG) were assessed by high-performance liquid chromatography. Expression of HSP70 and HSP90 in peripheral blood mononuclear cells was measured by Western blot. Results: Forty-five patients were enrolled to 11 dose levels between 10 and 395 mg/m 2 . The maximum tolerated dose was 295 mg/m 2 . Dose-limiting toxicity occurred in both patients (grade 3 pancreatitis and grade 3 fatigue) treated with 395 mg/m 2 . Common drug-related toxicities (grade 1 and 2) were fatigue, anorexia, diarrhea, nausea, and vomiting. Reversible elevations of liver enzymes occurred in 29.5% of patients. Hematologic toxicity was minimal. No objective responses were observed. 17AAG pharmacokinetics was linear. Peak plasma concentration and area under the curve of 17AG, the active major metabolite of 17AAG, increased with 17AAG dose, but the relationships were more variable than with 17AAG. 17AAG and 17AG in plasma were >90% protein bound. There were no consistent changes in peripheral blood mononuclear cell HSP90 or HSP70 content. Conclusions: 17AAG doses between 10 and 295 mg/m 2 are well tolerated. 17AAG pharmacokinetics is linear. Peripheral blood mononuclear cell HSP90 and HSP70 are uninformative pharmacodynamic markers. The dose recommended for future studies is 295 mg/m 2 weekly × 3, repeated every 4 weeks.